| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 1.93M | 2.72M | 2.68M | 2.46M | 2.69M |
| Revenue Growth % | - | 0.41% | -0.01% | -0.08% | 0.09% |
| Cost of Goods Sold | 481.09K | 467.66K | 297.06K | 303.35K | 362K |
| COGS % of Revenue | 0.25% | 0.17% | 0.11% | 0.12% | 0.13% |
| Gross Profit | 1.45M | 2.25M | 2.39M | 2.16M | 2.32M |
| Gross Margin % | 0.75% | 0.83% | 0.89% | 0.88% | 0.87% |
| Gross Profit Growth % | - | 0.56% | 0.06% | -0.1% | 0.08% |
| Operating Expenses | 5.57M | 5.22M | 5.76M | 8.82M | 9.48M |
| OpEx % of Revenue | 2.89% | 1.92% | 2.15% | 3.59% | 3.53% |
| Selling, General & Admin | 5.4M | 5.02M | 5.53M | 8.65M | 9.27M |
| SG&A % of Revenue | 2.8% | 1.84% | 2.06% | 3.52% | 3.45% |
| Research & Development | 166.8K | 203.41K | 225.61K | 169.31K | 206.11K |
| R&D % of Revenue | 0.09% | 0.07% | 0.08% | 0.07% | 0.08% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.12M | -2.97M | -3.37M | -6.66M | -7.16M |
| Operating Margin % | -2.13% | -1.09% | -1.26% | -2.71% | -2.66% |
| Operating Income Growth % | - | 0.28% | -0.14% | -0.98% | -0.07% |
| EBITDA | -4.08M | -2.93M | -3.34M | -6.62M | -7.12M |
| EBITDA Margin % | -2.12% | -1.08% | -1.24% | -2.69% | -2.65% |
| EBITDA Growth % | - | 0.28% | -0.14% | -0.99% | -0.07% |
| D&A (Non-Cash Add-back) | 35.79K | 36.71K | 37.13K | 40.73K | 37.83K |
| EBIT | -3.65M | -2.99M | -4.36M | -9.27M | -7.94M |
| Net Interest Income | -75.67K | -36.93K | -2.74M | -5.36M | -300.71K |
| Interest Income | 37 | 0 | -2.32M | -2.77K | 0 |
| Interest Expense | 75.71K | 36.93K | 417.6K | 5.36M | 300.71K |
| Other Income/Expense | 394.59K | -58K | -1.41M | -7.96M | -1.08M |
| Pretax Income | -3.73M | -3.03M | -4.78M | -14.63M | -8.24M |
| Pretax Margin % | -1.93% | -1.11% | -1.78% | -5.95% | -3.07% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% |
| Net Income | -3.73M | -3.03M | -4.78M | -14.63M | -8.24M |
| Net Margin % | -1.93% | -1.11% | -1.78% | -5.95% | -3.07% |
| Net Income Growth % | - | 0.19% | -0.58% | -2.06% | 0.44% |
| Net Income (Continuing) | -3.73M | -3.03M | -4.78M | -14.63M | -8.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.80 | -0.62 | -0.78 | -2.32 | -1.22 |
| EPS Growth % | - | 0.23% | -0.26% | -1.97% | 0.47% |
| EPS (Basic) | -0.80 | -0.62 | -0.57 | -2.32 | -1.22 |
| Diluted Shares Outstanding | 5.38M | 5.38M | 8.41M | 6.3M | 6.92M |
| Basic Shares Outstanding | 5.38M | 5.38M | 8.41M | 6.3M | 6.92M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 2.46M | 491.01K | 476.96K | 242.61K | 4.27M |
| Cash & Short-Term Investments | 1.9M | 320.86K | 253.7K | 78.56K | 3.7M |
| Cash Only | 1.9M | 320.86K | 253.7K | 78.56K | 3.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 311.33K | 115.3K | 174.4K | 73.17K | 244.62K |
| Days Sales Outstanding | 58.87 | 15.47 | 23.71 | 10.86 | 33.24 |
| Inventory | 106.85K | 39.18K | 48.13K | 21.22K | 44.33K |
| Days Inventory Outstanding | 81.06 | 30.58 | 59.14 | 25.53 | 44.7 |
| Other Current Assets | 0 | 0 | 726 | 69.66K | 280.37K |
| Total Non-Current Assets | 327.6K | 269.47K | 1M | 266.89K | 491.39K |
| Property, Plant & Equipment | 301.7K | 245.52K | 189.39K | 158.81K | 374.64K |
| Fixed Asset Turnover | 6.40x | 11.08x | 14.18x | 15.49x | 7.17x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 25.9K | 23.96K | 77.56K | 108.07K | 96.59K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 736.74K | 0 | 20.16K |
| Total Assets | 2.79M | 760.48K | 1.48M | 509.5K | 4.76M |
| Asset Turnover | 0.69x | 3.58x | 1.81x | 4.83x | 0.56x |
| Asset Growth % | - | -0.73% | 0.95% | -0.66% | 8.34% |
| Total Current Liabilities | 1.01M | 1.42M | 6.98M | 1.89M | 2.43M |
| Accounts Payable | 164.56K | 483.79K | 1.59M | 1.2M | 596.95K |
| Days Payables Outstanding | 124.85 | 377.59 | 1.96K | 1.45K | 601.89 |
| Short-Term Debt | 151K | 250.41K | 489.23K | 148.06K | 154.15K |
| Deferred Revenue (Current) | 0 | 69.34K | 59.17K | 74.95K | 32.53K |
| Other Current Liabilities | 8.49K | 43.84K | 4.51M | 341.7K | 1.27M |
| Current Ratio | 2.44x | 0.34x | 0.07x | 0.13x | 1.75x |
| Quick Ratio | 2.33x | 0.32x | 0.06x | 0.12x | 1.74x |
| Cash Conversion Cycle | 15.09 | -331.55 | -1.87K | -1.41K | -523.95 |
| Total Non-Current Liabilities | 137.18K | 161.29K | 76.2K | 27.07K | 256.5K |
| Long-Term Debt | 0 | 51.69K | 0 | 0 | 0 |
| Capital Lease Obligations | 137.18K | 109.59K | 76.2K | 27.07K | 256.5K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.15M | 1.59M | 7.05M | 1.91M | 2.69M |
| Total Debt | 311.49K | 439.27K | 598.82K | 224.26K | 473.4K |
| Net Debt | -1.58M | 118.42K | 345.12K | 145.7K | -3.22M |
| Debt / Equity | 0.19x | - | - | - | 0.23x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -54.43x | -80.43x | -8.08x | -1.24x | -23.80x |
| Total Equity | 1.64M | -825.66K | -5.57M | -1.4M | 2.07M |
| Equity Growth % | - | -1.5% | -5.75% | 0.75% | 2.47% |
| Book Value per Share | 0.31 | -0.15 | -0.66 | -0.22 | 0.30 |
| Total Shareholders' Equity | 1.64M | -825.66K | -5.57M | -1.4M | 2.07M |
| Common Stock | 2.52K | 2.55K | 1.96K | 6.51K | 6.99K |
| Retained Earnings | -26.12M | -29.15M | -33.93M | -48.56M | -56.8M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -4.14M | -2.23M | -2.3M | -6.69M | -6.1M |
| Operating CF Margin % | -2.14% | -0.82% | -0.86% | -2.72% | -2.27% |
| Operating CF Growth % | - | 0.46% | -0.03% | -1.91% | 0.09% |
| Net Income | -3.73M | -3.03M | -4.78M | -14.63M | -8.24M |
| Depreciation & Amortization | 35.79K | 36.71K | 37.13K | 40.73K | 37.83K |
| Stock-Based Compensation | 48.77K | 48.64K | 27.32K | 750K | 1.4M |
| Deferred Taxes | 0 | 41.11K | 0 | 0 | 0 |
| Other Non-Cash Items | -202.29K | 22.81K | 1.15M | 7.81M | 559.82K |
| Working Capital Changes | -295.45K | 644.43K | 1.27M | -665.75K | 141.4K |
| Change in Receivables | -223.01K | 184.26K | -78.6K | 75.95K | -178.84K |
| Change in Inventory | 323.76K | 67.67K | -8.95K | 26.91K | -32.5K |
| Change in Payables | -664.25K | 319.23K | 1.11M | -387.9K | -607.27K |
| Cash from Investing | -27.72K | -1.39K | -61.2K | -71.78K | -27.78K |
| Capital Expenditures | -27.72K | -1.39K | -1.39K | -30.78K | -27.78K |
| CapEx % of Revenue | 0.01% | 0% | 0% | 0.01% | 0.01% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | -59.81K | -41K | 0 |
| Cash from Financing | 6.05M | 661.1K | 2.29M | 6.59M | 9.74M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | 2.73M | -510K | -866.74K | -322.9K | -168.32K |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | -4.17M | -2.24M | -2.36M | -6.77M | -6.13M |
| FCF Margin % | -2.16% | -0.82% | -0.88% | -2.75% | -2.28% |
| FCF Growth % | - | 0.46% | -0.06% | -1.87% | 0.09% |
| FCF per Share | -0.77 | -0.42 | -0.28 | -1.07 | -0.89 |
| FCF Conversion (FCF/Net Income) | 1.11x | 0.74x | 0.48x | 0.46x | 0.74x |
| Interest Paid | 74.49K | 0 | 202.78K | 214.56K | 33.83K |
| Taxes Paid | 0 | 0 | 0 | 0 | 10.16K |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -226.69% | -740.29% | - | - | -2480.49% |
| Gross Margin | 75.08% | 82.81% | 88.94% | 87.67% | 86.52% |
| Net Margin | -193.04% | -111.27% | -178.05% | -594.57% | -306.84% |
| Debt / Equity | 0.19x | - | - | - | 0.23x |
| Interest Coverage | -54.43x | -80.43x | -8.08x | -1.24x | -23.80x |
| FCF Conversion | 1.11x | 0.74x | 0.48x | 0.46x | 0.74x |
| Revenue Growth | - | 40.98% | -1.34% | -8.37% | 9.18% |
| 2023 | 2024 | |
|---|---|---|
| CALIFORNIA | 601.24K | 778.21K |
| CALIFORNIA Growth | - | 29.44% |
| All other States | - | 767.99K |
| All other States Growth | - | - |
| OHIO | 407.63K | 431.33K |
| OHIO Growth | - | 5.81% |
| ILLINOIS | - | 246.22K |
| ILLINOIS Growth | - | - |
| MASSACHUSETTS | 127.3K | 154.41K |
| MASSACHUSETTS Growth | - | 21.29% |
| FLORIDA | 186.84K | 149.99K |
| FLORIDA Growth | - | -19.73% |
| All Other States | 844.44K | - |
| All Other States Growth | - | - |
NeurAxis, Inc. (NRXS) reported $3.4M in revenue for fiscal year 2024. This represents a 74% increase from $1.9M in 2020.
NeurAxis, Inc. (NRXS) grew revenue by 9.2% over the past year. This is steady growth.
NeurAxis, Inc. (NRXS) reported a net loss of $7.5M for fiscal year 2024.
NeurAxis, Inc. (NRXS) has a return on equity (ROE) of -2480.5%. Negative ROE indicates the company is unprofitable.
NeurAxis, Inc. (NRXS) had negative free cash flow of $6.3M in fiscal year 2024, likely due to heavy capital investments.